Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer

類似資料

• Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051
  著者:: Keita Miura, 等
  出版事項: (2024-02-01)
• Use of prophylactic pegfilgrastim for chemotherapy-induced neutropenia in the US: A review of adherence to present guidelines for usage
  著者:: Jeffrey Crawford, 等
  出版事項: (2021-01-01)
• Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L)
  著者:: Motoko Tachihara, MD, PhD, 等
  出版事項: (2023-10-01)
• Phase II study of ramucirumab and docetaxel for previously treated non‐small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study
  著者:: Shinnosuke Takemoto, 等
  出版事項: (2020-02-01)
• Interstitial lung disease induced by docetaxel and ramucirumab chemotherapy after nivolumab treatment
  著者:: Komugi Okeya, 等
  出版事項: (2020-07-01)